Design and engineering of a transmissible antiviral defense
© The Author(s) 2016
Received: 6 July 2016
Accepted: 19 September 2016
Published: 12 October 2016
We propose, model, and implement a novel system of population-level intervention against a virus. One context is a treatment against a chronic infection such as HIV. The underlying principle is a form of virus ‘wars’ in which a benign, transmissible agent is engineered to protect against infection by and spread of a lethal virus. In our specific case, the protective agent consists of two entities, a benign virus and a gene therapy vector mobilized by the benign virus.
Numerical analysis of a mathematical model identified parameter ranges in which adequate, population-wide protection is achieved. The protective system was implemented and tested using E. coli, bacteriophage M13 and a phagemid vector mobilized by M13 to block infection by the lethal phage T5. Engineering of M13 profoundly improved its dynamical properties for facilitating spread of the gene therapy vector. However, the gene therapy vector converts the host cell to resist T5 too slowly for protection on a time scale appropriate for T5.
Overall, there is a reasonable marriage between the mathematical model and the empirical system, suggesting that such models can be useful guides to the design of such systems even before the models incorporate most of the relevant biological details.
KeywordsTransmissible vaccine Bacteriophage Genetic engineering Virus
The most successful antiviral defenses are vaccines, working by blocking infection of the host. Unfortunately, vaccines are not available for many types of viral infections. Drugs are a second form of defense, usually applied after infection, but drugs commonly work poorly or succumb to rapid evolution of viral resistance ; with HIV, drug combinations work well at controlling infections but not curing. A third approach, specific to chronic infections such as HIV, is to introduce an infectious and replicating antiviral agent that interferes with the chronic virus in the same host. By limiting the density of the chronic virus in the host, symptoms of the infection are weakened and transmission of the chronic virus to new hosts is reduced.
The third approach of using one virus to thwart another within the same host (virus ‘wars’) has its roots with naturally occurring viral parasites known as defective interfering particles (DIPs). DIPs occur in many virus systems. They evolve to propagate themselves at the expense of their parent virus (known as a ‘helper’) and thereby offer a mechanism to suppress density of the parent/chronic virus [2, 3]. They equally point toward a much wider spectrum of interference mechanisms that are now feasible with genetic engineering. One novel design is to engineer a virus that specifically attacks cells infected with the chronic virus, killing them and replicating at the same time [4, 5]. A second design is to use a DIP to interfere with its ‘helper’ when the helper is the cause of symptoms [2, 6–8]. In the new method developed here, an engineered DIP and its helper virus are used in combination to resist infection by a third virus.
All variants of the virus wars approach have in common the use of one replicating virus to curtail propagation by another virus in the same host. Yet even with genetic engineering, ultimate success may prove challenging, requiring a suitable within-host ‘ecology’ and engineering exquisitely tailored to that ecology. It is not enough that the engineering cause the desired interference at the cellular level, the engineering must also satisfy dynamic constraints at the population level [6, 8, 9]. In these early days of designing such unprecedented interference mechanisms, success is likely to involve a continuing handshake between engineering, modeling, and empirical efforts. An important but unresolved question is where the generalities reside: will most of the hurdles lie in details specific to an application? Or will empirical generalities emerge that transcend the specific application? That question underlies the development of our model system here.
We propose a novel type of intervention against a chronic viral infection: a two-component system (similar to a DIP and its parent, helper virus) is engineered to work together in interfering with a third virus, a lethal virus. Our study is developed in three stages. First, we introduce the basic biology of our system. Second, this approximate biology is used to develop a mathematical model, which is then analyzed. Third, the biological components are assembled and their dynamical properties tested for fit to the model. A particular focus is the extent to which one can move from superficial biological properties to implementation. In this respect, our approach should serve as an example for other systems. The comparison of theoretical and empirical dynamics allows us to highlight the different hurdles thwarting success with the system and to propose how further engineering might overcome those hurdles.
A system like the one developed here could be used in a range of applications: as a transmissible vaccine, as a therapeutic virus administered to reduce symptoms in a patient already infected, or as a prophylactic vaccine. Our analyses do not explore all possible applications; rather they explore basic dynamics in a way that tests our understanding of the system and could thereby be used to improve various implementations.
A design from established biology
We develop an infectious, two-component gene therapy system to protect a host cell population against decimation by a lethal virus (the lethal virus is equivalent to the ‘chronic’ virus in our Introduction). The viruses are bacteriophages and the ‘host’ is a cell, the bacterium E. coli. The lethal virus is the lytic bacteriophage T5. The two component protection system consists of the non-lethal phage M13 and a separate, engineered plasmid that genetically converts the host cell to resist T5. To avoid confusion over different meanings of ‘host’ that are used in the infectious disease literature, we will henceforth refer to the bacterium as a ‘cell,’ ‘host cell’ or ‘bacterial host.’
Both elements of the two component system are needed to protect a population of cells. M13 spreads autonomously but does not protect its host cell, whereas the plasmid protects its host cell but cannot spread unless the cell also carries M13 – the plasmid is designed to be mobilized by M13. Given these asymmetries, we will refer to M13 as the ‘helper’ virus and the plasmid as ’vaccine.’
Cell and virus properties
Type of cell
If infected by
Cell dies; lethal virus produces progeny
Protected against lethal virus; remains susceptible to helper virus; cannot produce vaccine progeny
Remains susceptible to lethal virus; produces helper progeny; can no longer be infected by vaccine
Remains protected against lethal virus; now reproduces helper and vaccine progeny
Cell dies; lethal virus produces progeny
The Lethal Virus: Bacteriophage T5
Bacteriophage T5 is a lytic phage whose genome is just over 120kb of dsDNA and encodes up to 168 genes . It invariably causes a lethal infection of its bacterial host, with progeny released when the cell bursts. For infection, T5 requires the outer membrane receptor encoded by the bacterial gene fhuA. Knockout of fhuA renders the bacterium resistant to T5 infection and is the gene therapy target of our vaccine. As active cells have ≈ 1000 FhuA molecules per cell , resistance to T5 not only requires the knockout of fhuA but also loss of existing receptors, which may be achieved by dilution through cell division. Together, both processes may result in a substantial delay between vaccine infection and protection.
The Helper Virus: M13 phage
M13 is a non-lethal bacteriophage that infects F-piliated E. coli via attachment to the pilus. Its genome is 6407 bases of circular, single-stranded DNA, that upon infection, is converted to a dsDNA circle from which state all phage functions are expressed [12, 13]. Eleven protein coding genes are recognized, and an intergenic region contains several regulatory signals and is also suitable for insertion of cloned sequences.
M13 is atypical of most bacteriophages in that it does not lyse or kill its bacterial host; it establishes a persistent infection throughout the life of the host, and the infection is transmitted to daughter cells when the host divides. Phage progeny production is via continual secretion of phage virions through the cell wall and membranes – most virion assembly occurs as the genome is extruded through the membranes. M13 does adversely affect the growth rate and maximal cell density of the infected bacteria , but these fitness effects are minor in comparison to being killed (e.g., by T5).
Mobilizable Vaccine: a phagemid engineered to knock out a bacterial host receptor gene
M13 will process and package other circular genomes in the same cell if those genomes carry the appropriate regulatory sequences. Defective interfering particles  and engineered plasmids known as phagemids are packaged. Indeed, DIPs and phagemids act as parasites of M13 because they usurp resources that would otherwise go toward M13 progeny (see also below).
Our vaccine scaffold is a phagemid, an autonomous ColE1 plasmid, (ampicillin resistant) engineered to also carry the M13 origin of replication. When in a cell, the phagemid can replicate as a plasmid regardless of whether the cell also carries M13; it is transmitted to daughter cells. However, the phagemid cannot produce infectious particles unless the cell also carries M13, because the phagemid does not encode any of the proteins required for assembly. If M13 is also in the cell, it packages phagemid genomes which are then secreted as infectious particles. The M13 that mobilizes the phagemid is denoted a ’helper’ because of its indispensable role in mobilizing transmission of the phagemid, even though the helper is equally considered a selfish element being parasitized by the phagemid.
As with an M13 infection, phagemids infect bacteria using the F pilus of the cell. As phagemids infect via the same receptor used by M13, phagemids can only infect cells that have not been previously infected by M13, because infection by M13 leads quickly (within 15 min) to a block of infection by other M13 and related particles. However, the infection block is not symmetric: infection by a phagemid does not interfere with subsequent infection by M13.
We cloned a ‘targetron’  into the phagemid (the construct is henceforth denoted pgT) to act as our vaccine. Targetrons are programmable group II introns that can insert into a specified target gene on the bacterial chromosome. pgT was engineered to encode a targetron that inserts into the E. coli fhuA gene. When pgT infects the cell, the targetron inserts a copy of itself into the bacterial fhuA gene, disrupting its expression and thereby converting the cell to be genetically resistant to phage T5. The ability of the targetron to disrupt fhuA was tested by growing phagemid-infected cells overnight and plating on ampicillin and T5, which would kill T5-sensitive cells and kill any cells lacking the phagemid. 10 of 10 colonies were found by PCR to have the fhuA gene disrupted with an insert of the correct size. This test informs us that the construct converts cells to resist T5 at a rate higher than the background mutation rate.
The Bacterial Host: Escherichia coli
We used a lab strain of E. coli (IJ338, see Methods) that carries the F’ plasmid required by our vaccine helper phage. This strain also expresses the fhuA gene encoding the T5 receptor. Cells must be actively growing to allow for efficient and rapid amplification of phages.
A mathematical model of dynamics
Our empirical system lends itself to mathematical modeling; indeed modeling is required for a full understanding. We have two goals that benefit from mathematical models. One is to test the predictability of the empirical dynamics - are the dynamics robust to the many biological nuances of the system such that they can be captured despite the necessary approximations needed for modeling? The second goal is to explore dynamical behaviors that are not easily assayed empirically, perhaps because we cannot engineer the desired biology; the models can be a prelude to experimentation to decide which dynamical behaviors justify empirical testing.
Uninfected, susceptible bacterial cells (density H u ).
A lethal virus (density L) that, if unimpeded, will spread into the bacterial population and kill most cells.
A helper virus (density M) that, by itself, has little effect on the bacterial host and does not protect the bacterium from lethal virus infection/killing.
A phagemid vaccine (density V) that genetically converts the cell to block infection by the lethal virus; the phagemid is mobilizable by the helper virus but can infect only cells that are free of the helper virus.
The five states of infection accommodate cells infected with phagemid, with helper, helper plus phagemid, and whether cells with phagemid have become resistant to the lethal virus or are still sensitive.
The dynamics of this transmissible vaccine model system can be described by a system of differential equations [Eq. (A1), Appendix], with notation given in Table 4 in Appendix. These equations are tuned to the specific biology of our empirical system. Both the vaccine and helper elements establish life-long infections of the bacterial host and can transmit for life. They are also inherited by progeny.
The equations incorporate 14 parameters. Some of these can be gleaned to a suitable approximation from the extensive literature on phage biology, such as adsorption rates, burst sizes and lysis times of lytic phages [14, 17, 18]. Others, such as reproductive parameters and parameters specific to our engineering must be estimated as part of this study, as follows.
Output from infected cells
Reproductive rates of infected cells (per hr)
The estimates are highly variable, no doubt reflecting many factors that affect cell accommodation of the non-lethal phage. However, the engineered helper phage has far more desirable properties than does wild-type – the output of vaccine relative to helper (b VM : b MV ) is approximately 1:1 for wild-type and 100:1 for engineered (the benefit of which will be shown below). The engineering has also been accompanied by a reduction in the autonomous growth rate of the helper (b M ). (Note that the estimates in Table 2 are per hour to facilitate comprehension; those in Table 4 in Appendix are per minute.)
The vaccine can be effective only to the extent it confers resistance soon after infecting its bacterial host. There are several steps between infection by a phagemid and resistance to T5. The targetron must first integrate into fhuA and inactivate its function. Then existing FhuA receptors must decay or be diluted. With 1000 receptors per cell and no decay of existing FhuA, complete protection of half the population would require at least 10 generations after integration (assuming that receptors are equally distributed across daughters), but substantial levels of protection would possibly be achieved well before this time.
Population-level vaccine protection against lethal virus
Lag between vaccine and lethal virus addition a
Fold drop in concentration/titer of vaccine-infected cells due to T5 killing b
Both assays allow the same conclusion. Resistance to T5 is slow to be attained, at least on a scale of hours. The Eqs. (A1) assume that cells infected with vaccine become T5 resistant at a constant rate; we consider a value of c=0.001 (/min) to be a suitable approximation to these results (an average of 16.7 hr, with half the population becoming resistant in 11.5 hr). For the sake of model analysis, Table 4 in Appendix also includes a value of c=0.1 to consider the possible benefits of improved engineering of this parameter value.
Model dynamics of vaccine and helper virus only
The most pressing question is whether a vaccine that must be mobilized by a helper virus can spread completely enough to protect most or all of the population, even in the absence of the lethal virus. If the vaccine cannot spread well, any protection it affords will necessarily be minimal. Intuition suggests that the dynamics are not favorable for vaccine spread in this system: the vaccine cannot spread by itself and it also cannot infect a cell already infected with the helper virus, whereas the helper virus faces neither constraint. Therefore the dynamics appear to favor the helper virus over the vaccine, an outcome that would fully undermine the two-component system. Alternatively if vaccine spread is merely sensitive to parameter values, then the models may guide efforts to engineer strains whose biology is compatible with favorable dynamics. Indeed, it is well known that DIPS can vastly out-reproduce their parent (helper) virus at high density, offering hope that conditions can be identified (or engineered) that will allow our vaccine to prevail.
A suggestion from Fig. 2 is that vaccine spread may depend heavily on the reproductive parameters of the vaccine and helper, but few values were tried. The problem is challenging to grasp intuitively because of the multiple effects of helper reproduction: a helper that spreads rapidly on its own may block vaccine spread, yet helper spread also indirectly facilitates vaccine spread. A large set of runs was conducted to explore the sensitivity of outcomes to three reproductive parameters: (i) autonomous helper reproduction rate (b M , progeny from a helper-infected cell, per minute), (ii) vaccine output from a doubly-infected cell (b VM ), and (iii) helper reproduction rate from a doubly-infected cell (b MV ).
There is substantial improvement from increasing the number of individuals vaccinated at the outset. This benefit of increased ‘manual’ vaccinations likely stems from the ability of the helper virus but not the vaccine to propagate autonomously and from the vaccine being blocked at infecting a helper-infected cell. If the number of doubly-infected cells added to the culture is very low, their vaccine and helper progeny will tend to infect different cells. Helper-infected cells continue transmitting helper virus and gradually spread throughout the bacterial population (creating bacteria that cannot be infected by vaccine). In contrast, vaccine-infected cells do not transmit until the cell is later infected by helper. Thus early transmission disproportionately favors the helper when the number of manual vaccinations is low. As the number of early manual vaccinations increases, subsequent transmission dynamics increasingly involve the vaccine.
These analyses point to the utility of an approach that combines engineering with dynamic analysis: engineering is used to control the vaccine:helper output ratio from doubly-infected cells, whereas the dynamics analyses indicate what level of manual vaccination is required for a desired final level of vaccine coverage. These analyses also suggest that any process which increases the local density of phages (spatial structure or increased initial vaccinations) or increases co-transmission of helper and vaccine would improve vaccine coverage. These speculations point toward obvious directions for future work.
Model dynamics of the full system
Many qualitative properties of the full system (vaccine, helper, lethal virus) follow from the preceding analyses. The vaccine can offer significant protection only to the extent it transmits well enough to reach much of the population and it is introduced enough in advance of the lethal virus that it has time to spread and time to protect the cells that it reaches. Absent a sufficiently early vaccine introduction, the lethal virus will kill most of the population, at which point, the few vaccinated cells will dominate the survivors (some bacteria will be resistant because of spontaneous mutations that disable fhuA). As noted above, there could be a long lag between acquiring the vaccine and being protected by it (given by parameter c), in which case, even an early vaccine introduction may not be sufficient.
From panels (a)–(c), it is easily seen that helper-infected cells (light blue) quickly become the dominant cell population until the lethal virus ascends and kills them. They are intrinsically doomed because the vaccine cannot infect them. The goal, then, is to shift the dynamics toward cells infected with the vaccine. That goal is largely achieved in panel (d), by increasing the reproductive output 10-fold from doubly-infected cells (b VM , b MV ). Compared to panel (a), which otherwise used the same run conditions, there is a substantial improvement in protection due to replacing helper-infected cells with doubly-infected cells. Panels (e) and (f) invoke a 10-fold reduction in burst size (fecundity) of the lethal virus; here cell and vaccine dynamics are not impacted by the lethal virus in the time frame shown. Thus the dynamics that operate in the absence of the lethal virus obtain in the short run for these conditions.
Empirical dynamics of vaccine and helper
Other observations are at variance with the models. (3) Vaccine infection levels at the 3-h endpoint are not obviously correlated with the double infections introduced at time 0; the highest vaccine coverage at 3 h occurred in the trial with the lowest input of double infections. (4) Two trials show a 100-fold rise in doubly-infected cells from hour 1 to hour 3. Growth of doubly-infected cells can explain at most a 20-fold increase over two hours (Table 3), yet infection levels in the population do not support high enough infection rates to explain the further 5-fold increase.
These discrepancies appear to be the usual, generic quantitative nuances that arise in most empirical attempts at a priori tests of quantitative models. They may arise from difficulty in controlling initial conditions, or more fundamentally, they may arise from systematic violations of the assumptions. As a possible example of the latter type, the cells used here may not be uniformly susceptible to infection, due to non-genetic variation in F pilus expression. The F pilus must be extended for M13 and phagemid infection, but the F pilus oscillates between the extended and retracted states. If some cells are more prone to have the pilus retracted (as suggested in previous work, [14, 19]), they will be less susceptible to infection by both M13 and the vaccine. Conversely, cells acquiring the vaccine would also be prone to acquire the helper. Such a process could explain a state in which there is both an abundance of double infections and also an abundance of uninfected cells. There also seems to be little that can be done about the problem, but it is clearly a property of the system that could be included in refined models.
Empirical dynamics of the full system
In the treatment of chronic viral infections such as HIV, the so-far failure of standard vaccine approaches combined with the failure of drugs to cure infections (although providing ongoing HIV suppression) have led to suggestions of novel interventions. One class of these interventions is to infect the patient with viral agents that interfere with the chronic infection. Proposals have ranged from introducing viruses that kill HIV-infected cells to sub-genomic viruses that merely suppress HIV reproduction when both are in the same cell [2, 6–8]. Here, we used a model system to explore yet another approach, an engineered viral system to infect cells and convert them to block infection by the chronic virus. The method does not necessarily eradicate the chronic virus at the population level, but it creates and dynamically maintains a subset of cells that are protected from infection.
The specific implementation we tested was that of a two-component ‘vaccine’ system. One viral agent is essentially a gene therapy vector that infects a cell and subsequently prevents infection by the chronic virus. However, by itself, this vector does not transmit between cells; it requires a second (non-lethal virus) to mobilize it. On the surface, the requirement of two components appears to be dynamically unfavorable. It is indeed unfavorable, but numerical studies indicated that certain regions of parameter space lead to acceptable outcomes. Those favorable regions require engineering the reproductive properties of vaccine and helper virus.
One of our main goals was to contrast models developed from an understanding of the basic biology of the therapeutic agents with performance in actual implementations by using bacteriophages. This exercise should help guide future efforts, which are often developed from general principles. There were in fact several challenges in implementation. First, our vaccine was slow to protect cells against the lethal virus (phage T5). Thus, a prohibitively long advance delivery of the two-component system was required to achieve substantial protection in our system. Second, reproductive rates of the vaccine and helper virus were not quite in the optimal range for dynamical coverage of the population, although engineering the helper virus greatly improved its performance. It is conceivable that either or both of these imperfections could be mitigated by further engineering.
The success of a 2-component vaccine may be improved by increasing co-transmission of helper and vaccine to the same host. Here, transmission was likely independent – phagemids (vaccine) and M13 helper are produced as separate particles and, in the mass action realm of liquid culture, would usually encounter hosts independently of each other. Co-transmission should improve vaccine success because more hosts would receive the vaccine at the same time as the helper, reducing the number of cells that get only the vaccine or only the helper (neither of which transmit vaccine). M13 can evolve to co-package genomes from the same cell , so the system used here might be suitable for testing the effect of co-transmission. Co-transmission between a wild-type and a defective dengue virus has recently been reported , suggesting that co-transmission may be a feasible strategy in many systems.
A similar type of interference mechanism as here could be achieved by engineering a single therapeutic vaccine (instead of a two-component vaccine). A single therapeutic virus would have favorable dynamics over a much larger parameter space. Yet there are likely downsides of engineered single-component systems. A two-component system is easier to engineer and more likely to be evolutionarily stable than a single-component system. If the single-genome vaccine is merely an attenuated (genetically weakened) version of the wild-type, there is an inherent risk of the vaccine evolving back to high virulence, much as observed with the live polio vaccine [22, 23]. Alternatively, a single-genome, ‘subunit’ vaccine that encodes an antigenic insert may not revert to high virulence (if the genomic backbone is avirulnet), but it may instead readily evolve to lose the insert because the subunit is detrimental to spread of the genetic backbone . Two-component systems should be more stable against these unwanted outcomes. But the final choice of which design to use may depend on details specific to the application.
Although our system is most easily construed as a within-host therapy against a chronic viral infection, it has broad parallels with transmissible vaccines [6, 8, 9, 14]. In this latter context, the bacterial cells would represent the multicellular hosts, and all within-host dynamics are subsumed within the individual bacterial cells. The usual interpretation of a transmissible vaccine is as a single, self-transmissible agent, but our 2-component system has close parallels with a proposed anti-HIV system [6, 8, 9].
It has been possible to develop and predict approximate empirical behavior of a novel 2-component, transmissible gene therapy system from first principles. The system is intended to protect a population of host cells from eradication by a lethal virus. With only broad-scale parameterization, empirical studies and mathematical models are in broad agreement. Some dynamic anomalies suggest that refinements of the models are justified in yielding better agreement, but the existing agreement is encouraging if not impressive. Despite intuition that a two-component system is intrinsically unfavorable for population protection, the models identified parameter values where the outcome is favorable. In one respect (relative transmission rates of vaccine and helper), the system was engineered toward this favorable outcome. Yet in another important aspect, the system failed (conversion of the cell to resistance was unacceptably slow). Future efforts with this system should be directed to improving the conversion rate. Even so, at this stage the models are successful enough to justify using them in comparing different ‘virus wars’ approaches to determine which ones are best applied to different contexts.
Calculating particle output
When measuring bacterial and phage concentrations/titers at two time points, the only unknown in Eq. (5) is b M . For particle production from doubly-infected cells, the equations are applied separately.
Strains and media
Media. Bacteria and phages were cultured in LB broth (10g NaCl, 10g Bacto tryptone, 5g Bacto yeast extract per liter). Plates contained LB with 15g Bacto agar per liter. When measuring phage concentrations, soft agar (7 g Bacto agar per liter) was used to overlay LB plates.
Bacteria and phages and phagemid. Escherichia coli IJ338  was used as the host for dynamics experiments. Phagemid pBluescript SK(+) (ampicillin resistant), engineered to carry a targetron gene programmed to disrupt E. coli gene fhuA, was used as the vector for delivery of the vaccine (named pgT, see below). The wild-type M13 phage was JB5 , an f1 (M13) with a kanamycin resistance gene cloned into the intergenic region. (Wild-type phages f1 and M13 are nearly identical in sequence and are considered equivalent.) The commercial helper phage M13KO7 (also Kn-resistant) was used as an M13 engineered to overproduce phagemid. Bacteriophage T5 was the lethal virus.
The LtrB intron donor plasmid pACD4-G  was modified to target the E. coli fhuA gene. Predicted fhuA insertion sites and gBlock designs for retargeting the LtrB intron were generated using TargeTronics, LLC (www.targetrons.com). The predicted site with the highest score (LtrB insertion occurring between base-pairs 1446|1447 on fhuA) was selected for TargeTron reprogramming (nucleotide sequence coordinates after LtrB insertion into the fhuA gene: 5’-TATGTTCAGGATCAGGCGCAGTGGGATAAA- LtrB -GTGCTGGTTACGCTT). The gBlock fragment (obtained from IDT) used to modify the LtrB intron in pACD4-G was PCR amplified, purified in a 0.8 % agarose gel, digested with HindIII and BsrGI, and swapped with the corresponding fragment in the pACD4-G donor plasmid (named pACD4-fhuA). Modification was confirmed using Sanger sequencing.
Essential targetron genes (LtrB intron and LtrA) were cloned into pBluescript(SK+) to generate the pgT construct by digesting pACD4-fhuA with EcoO109I and HindIII, purifying in a 0.8 % agarose gel, and swapping with the corresponding fragment on pBluescript(SK+). pgT was transformed into IJ338 and targetron insertion into the bacterial fhuA gene was confirmed via PCR amplicon size.
To generate the pgT phage stocks, pgT-infected IJ338 was grown in LB + Amp culture, infected with M13KO7 helper phage, and plated on LB agar plates with Kn and Amp to select for colonies doubly infected with pgT and M13KO7. Colonies were picked and grown overnight in LB with Amp and Kn. The overnight culture was incubated at 65 °C for 60 minutes to kill bacteria, spun down and the supernatant containing pgT and M13KO7 phage particles was collected.
Cultures were incubated at 37 °C. Dynamics were carried out in 10 mL volumes of LB broth. Frozen stocks of bacteria (IJ338) were made by concentrating exponentially growing cells (grown in LB broth), aliquoting and freezing in 20 % LB glycerol. Frozen stocks were stored at -80°C. Cells were thawed just before use and added to 10 mL LB broth in 125 mL flasks and grown with aeration (170 rpm) for 60 min to a density of ∼108 cells/ml, at which point T5 phage or pgT was added, depending on the dynamics being tested. The volumes were diluted 10X when cell densities were high enough to inhibit further host growth.
Densities of T5 were measured as plaque-forming units in soft agar on a lawn of sensitive bacteria. Densities of phagemid and M13 were determined by an overlay method  as follows. Sensitive cells were mixed in soft agar and spread on LB agar plates to create a lawn. After this layer set, phage suspended in 2-4 μL were streaked on top of the lawn and allowed to dry. A second, empty layer of soft agar was poured and allowed to set (this layer prevents cells from being spread when the third layer is poured). The plate was incubated for 1–2 h at 37 °C to allow infection. Antibiotic corresponding to the resistance carried by f1 was then mixed with soft agar and overlain on top so that only cells infected with f1 would form colonies.
Testing for incidence of T5 resistance
In both assays, a suspension of pgT particles was added at an MOI of 1.0 to a culture of IJ338 that had been grown for 1 h. IPTG was added to 1 mM to induce targetron expression. In one assay, cells were plated separately on ampicillin and on a high density of T5 at 1, 4 and 8 h. 100-fold dilutions were made every 2-3 h to prevent resources from limiting host growth. In the other assay, T5 was added to the culture, grown for 3–4 h, and the culture plated for surviving cells.
Dynamics with both phages
A suspension of the vaccine (pgT) was added to a culture of cells grown for 1 h to a density of ∼108 phage/ml; IPTG was present (1 mM) to induce expression of the targetron gene. The culture was grown for 3 h, 7 h, or overnight (minimally 14 h). For overnight growth, the culture was diluted 10X at the start, then diluted 10X the following morning and grown for an additional hour before addition of T5. Phage T5 was added at a density of ∼106 phage/ml. Bacteriophage samples were taken at each hour and cell densities were measured via plating on agar plates and incubating overnight at 37 °C. Samples of pgT were purified by incubating the sample at 65 °C for 60 minutes to kill bacteria and T5, centrifuging debris and collecting the supernatant. T5 samples were purified by mixing sample with chloroform to kill phagemid, M13 and bacteria, centrifuging and collecting supernatant. pgT numbers were measured as described above. T5 concentrations were measured by counting plaques on a lawn of sensitive cells. To determine the fraction of cells infected with pgT at each time point, colonies grown in the absence of drug were stabbed onto new agar plates containing ampicillin.
Dynamics with T5 in the absence of vaccine protection
T5 was added to a growing culture of cells at a density of ∼2×109 phage/ml. Each hour, phage were collected as described above and cells were plated on LB agar plates for density. T5 phage concentration was measured by counting plaques on a lawn of sensitive IJ338.
Dynamics of the two component vaccine in the absence of lethal virus
IJ338 was infected with a suspension of pgT plus M13KO7 and plated on LB containing kanamycin and ampicillin to select bacteria infected with both phage-types. 10-15 colonies were picked and grown in LB containing Amp and Kn overnight. The following day, IJ338 was grown for 1 h to a concentration between 5×107 and 1×108 cells/ml. At 1 h, the culture of doubly-infected cells was spun down at 2000 rpm for 2 minutes, resuspended in LB, and added to the IJ338 culture at a concentration between 5×104 and 8×105 cells/ml. Cell densities were measured at 0, 1, and 3 h via plating. Total density was determined by plating on LB agar plates while densities of pgT-infected and M13KO7-infected bacteria were measured by plating on LB agar plates containing Amp and Kn respectively. To determine the fraction of cells doubly infected (with phagemid and helper phage) or singly infected (phagemid alone or helper phage alone), colonies from the kanamycin and ampicillin plates were stabbed onto separate plates with ampicillin and kanamycin respectively.
Model variables and parameters
Density of vaccine (free particles)
Density of helper virus (free particles)
Density of lethal virus (free particles)
Density of uninfected cells
Density of cells infected with vaccine but still sensitive to lethal virus
Density of cells infected with vaccine and resistant to lethal virus
Density of cells infected with helper
Density of cells infected with vaccine and helper but still sensitive to lethal virus
Density of cells infected with vaccine and helper and resistant to lethal virus
Density-adjusted growth factor for all cells [ =1−(H u +H M +H VS +H VR +H VMS +H VMR )/C]
Adsorption rate of vaccine to uninfected cells (mL/min)
Adsorption rate of helper virus to all cells that it infects (mL/min)
Adsorption rate of lethal virus to all cells that it infects cells (mL/min)
Intrinsic growth rate of uninfected cells (/min)
Intrinsic growth rate of vaccine-infected cells (/min)
Intrinsic growth rate of helper-infected cells (/min)
Intrinsic growth rate of cells infected with vaccine and helper (/min)
Rate of conversion to T5 resistance by vaccine-infected cells (/min)
Rate at which helper-infected cells produce helper (/min)
Rate at which vaccine-infected, helper-infected cells produce vaccine (/min)
Rate at which vaccine-infected, helper-infected cells produce helper (/min)
Burst size of a cell infected with lethal virus
Time after infection that a cell infected with the lethal virus dies (min)
Carrying capacity of environment
Appendix: Equations of dynamics
We use ordinary differential equations to model phage dynamics, as has been standard for many decades . A superior dot over a variable indicates a derivative with respect to time. Nine variables and 14 parameters specify behavior of the cells and viruses in our system. Infection rates are assumed to follow mass action, the number of host cells infected being the product of host density, viral (or vaccine) density, and an adsorption rate parameter (k). The lethal virus releases b viral progeny τ minutes after infection (a parenthetical t−τ indicates the value τ minutes in the past). Lethal infections have such a short lifespan that the equation is omitted for cells infected with the lethal virus. As our model assumes a closed system, it includes a logistic growth function (G) to limit host density to a carrying capacity. Although our helper virus (M13) is known to adversely affect maximal density to a small degree , we use a common carrying capacity for uninfected cells and helper-infected cells.
R  (ggplot2  and cowplot ) was used to generate figures. Mathematica 10.4.0.0 and 184.108.40.206 were used for numerical analyses. A Mathematica file used to generate panels in Fig. 4 is provided as Additional file 2.
This material is based in part upon work supported by the National Science 401 Foundation (BEACON Center) under Cooperative Agreement No. DBI-0939454. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation. Also supported by NIH GM 57756 to JJB.
Availability of data and material
All data generated or analyzed during this study are included in this published article or Additional file 1.
The study was designed by JJB with help from ADE and IJM. Nearly all empirical work was carried out by MLP. Mathematical analyses were carried out by JJB, SLN, and RM. Manuscript was written and figures generated by JJB and MLP. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Richman DD. Antiviral Drug Resistance, 1st ed. Chichester; New York: Wiley; 1996.Google Scholar
- Barrett AD, Dimmock NJ. Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol. 1986; 128:55–84.View ArticleGoogle Scholar
- Marriott AC, Dimmock NJ. Defective interfering viruses and their potential as antiviral agents. Rev Med Virol. 2010; 20(1):51–62. doi:10.1002/rmv.641.View ArticleGoogle Scholar
- Mebatsion T, Finke S, Weiland F, Conzelmann KK. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell. 1997; 90(5):841–7.View ArticleGoogle Scholar
- Schnell MJ, Johnson JE, Buonocore L, Rose JK. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell. 1997; 90(5):849–57.View ArticleGoogle Scholar
- Weinberger LS, Schaffer DV, Arkin AP. Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol. 2003; 77(18):10028–36.View ArticleGoogle Scholar
- Easton AJ, Scott PD, Edworthy NL, Meng B, Marriott AC, Dimmock NJ. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine. 2011; 29(15):2777–84. doi:10.1016/j.vaccine.2011.01.102.View ArticleGoogle Scholar
- Ke R, Lloyd-Smith JO. Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors. PLoS Comput Biol. 2012; 8(10):1002744. doi:10.1371/journal.pcbi.1002744.MathSciNetView ArticleGoogle Scholar
- Metzger VT, Lloyd-Smith JO, Weinberger LS. Autonomous targeting of infectious superspreaders using engineered transmissible therapies. PLoS Comput Biol. 2011; 7(3):1002015. doi:10.1371/journal.pcbi.1002015.View ArticleGoogle Scholar
- Wang J, Jiang Y, Vincent M, Sun Y, Yu H, Wang J, Bao Q, Kong H, Hu S. Complete genome sequence of bacteriophage T5. Virology. 2005; 332(1):45–65. doi:10.1016/j.virol.2004.10.049.View ArticleGoogle Scholar
- Boulanger P, le Maire M, Bonhivers M, Dubois S, Desmadril M, Letellier L. Purification and structural and functional characterization of FhuA, a transporter of the Escherichia coli outer membrane. Biochemistry. 1996; 35(45):14216–24. doi:10.1021/bi9608673. Accessed 29 Mar 2016.View ArticleGoogle Scholar
- Marvin DA, Hohn B. Filamentous bacterial viruses. J Biosci. 1969; 33(2):172–209. doi:10.1007/BF02702778.Google Scholar
- Russel M, Model P. Filamentous Phage In: Calendar R, editor. The Bacteriophages. 2nd ed. New York: Oxford University Press: 2006. p. 146–60.Google Scholar
- Paff ML, Nuismer SL, Ellington A, Molineux IJ, Bull JJ. Virus wars: using one virus to block the spread of another. PeerJ. 2016; 4:2166. doi:10.7717/peerj.2166.View ArticleGoogle Scholar
- Horiuchi K. Co-evolution of a filamentous bacteriophage and its defective interfering particles. J Mol Biol. 1983; 169(2):389–407.View ArticleGoogle Scholar
- Perutka J, Wang W, Goerlitz D, Lambowitz AM. Use of computer-designed group II introns to disrupt Escherichia coli DExH/D-box protein and DNA helicase genes. J Mol Biol. 2004; 336(2):421–39.View ArticleGoogle Scholar
- Adams MH. Bacteriophages. New York: Interscience Publishers; 1959.Google Scholar
- Levin BR, Stewart FM, Chao L. Resource - limited growth, competition, and predation: a model and experimental studies with bacteria and bacteriophage. Am Nat. 1977; 977:3–24.View ArticleGoogle Scholar
- Lenski RE. Dynamics of interactions between bacteria and virulent bacteriophage. Adv Microb Ecol. 1988; 10:1–44. doi:10.1007/978-1-4684-5409-3_1.View ArticleGoogle Scholar
- Sachs JL, Bull JJ. Experimental evolution of conflict mediation between genomes. Proc Natl Acad Sci USA. 2005; 102(2):390–5. doi:10.1073/pnas.0405738102.View ArticleGoogle Scholar
- Ke R, Aaskov J, Holmes EC, Lloyd-Smith JO. Phylodynamic analysis of the emergence and epidemiological impact of transmissible defective dengue viruses. PLoS Pathog. 2013; 9(2):1003193. doi:10.1371/journal.ppat.1003193.View ArticleGoogle Scholar
- Kew O. Reaching the last one per cent: progress and challenges in global polio eradication. Curr Opin Virol. 2012; 2(2):188–98. doi:10.1016/j.coviro.2012.02.006.View ArticleGoogle Scholar
- Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014; 210 Suppl 1:283–93. doi:10.1093/infdis/jiu295.View ArticleGoogle Scholar
- Gladstone EG, Molineux IJ, Bull JJ. Evolutionary principles and synthetic biology: avoiding a molecular tragedy of the commons with an engineered phage. J Biol Eng. 2012; 6(1):13. doi:10.1186/1754-1611-6-13.View ArticleGoogle Scholar
- Messenger SL, Molineux IJ, Bull JJ. Virulence evolution in a virus obeys a trade-off. Proc Biol Sci R Soc. 1999; 266(1417):397–404. doi:10.1098/rspb.1999.0651.View ArticleGoogle Scholar
- R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. http://www.R-project.org/.Google Scholar
- Wickham H. Ggplot2: Elegant Graphics for Data Analysis. New York: Springer; 2009.View ArticleMATHGoogle Scholar
- Wilke CO. Cowplot: Streamlined Plot Theme and Plot Annotations for ‘ggplot2’. 2015. R package version 0.6.0. https://CRAN.R-project.org/package=cowplot.